托维妥单抗
化合物
托维妥单抗（INN：Tovetumab）是一种抗PDGFRA单克隆抗体，设计用于治疗癌症。[1]它由MedImmune开发，并试验用于胶质母细胞瘤和非小细胞肺癌。[2]对于该药物的开发于2013年停止。[3][4]
| 单克隆抗体 | |
|---|---|
| 种类 | ? |
| 目標 | PDGFRA |
| 臨床資料 | |
| ATC碼 |
|
| 识别信息 | |
| CAS号 | 1243266-04-7 |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6400H9906N1726O2002S54 |
| 摩尔质量 | 144,792.97 g·mol−1 |
存卡里
- ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Tovetumab, American Medical Association.
- ^ Liang M, Wang B, Schneider A, Vainshtein I, Roskos L. A Novel Pharmacodynamic Biomarker and Mechanistic Modeling Facilitate the Development of Tovetumab, a Monoclonal Antibody Directed Against Platelet-Derived Growth Factor Receptor Alpha, for Cancer Therapy. The AAPS Journal. November 2020, 23 (1): 4. PMID 33210183. S2CID 227067803. doi:10.1208/s12248-020-00523-3
.
- ^ Tovetumab. AdisInsight. Springer Nature Switzerland AG. [2024-03-01]. （原始内容存档于2017-11-03）.
- ^ Williams R. Discontinued in 2013: oncology drugs. Expert Opinion on Investigational Drugs. January 2015, 24 (1): 95–110. PMID 25315907. S2CID 23390614. doi:10.1517/13543784.2015.971154.
